These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24756419)
1. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Hu Y; Petroni GR; Olson WC; Czarkowski A; Smolkin ME; Grosh WW; Chianese-Bullock KA; Slingluff CL Cancer Immunol Immunother; 2014 Aug; 63(8):779-86. PubMed ID: 24756419 [TBL] [Abstract][Full Text] [Related]
2. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019 [TBL] [Abstract][Full Text] [Related]
3. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475 [TBL] [Abstract][Full Text] [Related]
4. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025 [TBL] [Abstract][Full Text] [Related]
5. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. Slingluff CL; Petroni GR; Yamshchikov GV; Hibbitts S; Grosh WW; Chianese-Bullock KA; Bissonette EA; Barnd DL; Deacon DH; Patterson JW; Parekh J; Neese PY; Woodson EM; Wiernasz CJ; Merrill P J Clin Oncol; 2004 Nov; 22(22):4474-85. PubMed ID: 15542798 [TBL] [Abstract][Full Text] [Related]
6. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
7. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732 [TBL] [Abstract][Full Text] [Related]
8. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590 [TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377 [TBL] [Abstract][Full Text] [Related]
15. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639 [TBL] [Abstract][Full Text] [Related]
16. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401 [TBL] [Abstract][Full Text] [Related]
17. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560 [TBL] [Abstract][Full Text] [Related]
18. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780 [TBL] [Abstract][Full Text] [Related]